di-tert-butyl [4,4'-bipiperidine]-1,1'-dicarboxylate

Catalog No.: 
ACTQCS762
CAS No.: 
165528-89-2
Molecular Formula: 
C20H36N2O4
Molecular Weight: 
368.27
di-tert-butyl [4,4'-bipiperidine]-1,1'-dicarboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$56.00In stockInquiry
1g95%$120.00In stockInquiry
5g95%$401.00In stockInquiry
25g95%$1556.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Namedi-tert-butyl [4,4'-bipiperidine]-1,1'-dicarboxylate
IUPAC Namedi-tert-butyl [4,4'-bipiperidine]-1,1'-dicarboxylate
MDL No.MFCD16621679
Molecular FormulaC20H36N2O4
Molecular Weight368.27
SMILESO=C(N1CCC(C2CCN(CC2)C(OC(C)(C)C)=O)CC1)OC(C)(C)C
InChI KeyLTWYWFHCRIFTIF-UHFFFAOYSA-N
SynonymN-BOC-N-BOC-4,4-BIPIPERIDINE;[4,4'-Bipiperidine]-1,1'-dicarboxylic acid, 1,1'-bis(1,1-dimethylethyl) ester;Di-tert-butyl [4,4'-bipiperidine]-1,1'-dicarboxylate
CAS No.165528-89-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H319
Precautionary Statement(s)
P305+P351+P338

Synthetic Route by SureRoute

1. ACTQCS762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKMFA710 route compound structure diagram
    ACKMFA710171049-35-7In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTQCS762 route product structure diagram
    ACTQCS762165528-89-2In Stock
Inquiry

2. ACTQCS762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTQCS762 route product structure diagram
    ACTQCS762165528-89-2In Stock
Inquiry

3. ACTQCS762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTQCS762 route product structure diagram
    ACTQCS762165528-89-2In Stock
Inquiry

Comments (0)